-

GE HealthCare Names James Saccaro Vice President and Chief Financial Officer

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, has named James "Jay” Saccaro as vice president and chief financial officer (CFO), succeeding Helmut Zodl who is remaining with the Company to lead special projects regarding separation from GE. These changes will take effect June 1, 2023.

Saccaro joins GE HealthCare from Baxter International, a global medtech leader, where he has been serving as its executive vice president and CFO since 2015. Prior to rejoining Baxter, he was senior vice president and CFO at Hill-Rom Corporation. Saccaro had previously served as corporate vice president and treasurer of Baxter from 2011 to 2013. He originally joined that company in 2002 as manager of strategy for Baxter’s BioScience business, and over the years assumed positions of increasing responsibility, including vice president of financial planning, and vice president of finance for the company’s operations in Europe, Middle East, and Africa. Saccaro received a bachelor’s degree in economics and master’s degree in engineering-economic systems from Stanford University.

“I am excited that Jay has agreed to serve as our CFO, as our company executes on our strategic growth plan and achieves our purpose to create a world where healthcare has no limits and continues to deliver on our promises to customers and shareholders. Jay is a world-class CFO bringing deep knowledge of the medtech and bioscience industries to GE HealthCare, coupled with excellent strategic and operational skills and extensive experience in leading large global organizations,” said GE HealthCare President and CEO Peter Arduini. “I want to thank Helmut for his leadership during the leadup and spin-off from GE and for creating tremendous momentum that we will continue to build on under Jay.”

“I am thrilled to join GE HealthCare and be part of the exciting innovation the company is driving within the precision care space,” said Saccaro. “This is an outstanding team with a clear strategic vision, deep experience, and a commitment to financial discipline. I look forward to leading the finance organization as GE HealthCare executes on its strategy of delivering profitable growth and value creation for shareholders.”

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Follow us on LinkedIn, Twitter, and Insights for the latest news, or visit our website gehealthcare.com for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com

Media Contact:
Tor Constantino
+1-585-441-1658
tor.constantino@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Summary
GE HealthCare has named James "Jay” Saccaro as vice president and chief financial officer (CFO), succeeding Helmut Zodl, who will remain at GEHC.
Release Versions

Contacts

Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com

Media Contact:
Tor Constantino
+1-585-441-1658
tor.constantino@gehealthcare.com

More News From GE HealthCare

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the I...

GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations

CHICAGO--(BUSINESS WIRE)--At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey. According to t...

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,i an innovative photon‑counting computed tomography (PCCT) solution powered by the company’s novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spec...
Back to Newsroom